Mural Oncology (NASDAQ:MURA – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($0.05), RTT News reports.
Mural Oncology Stock Performance
NASDAQ:MURA traded up $0.17 during trading hours on Tuesday, reaching $3.80. The stock had a trading volume of 146,728 shares, compared to its average volume of 162,217. Mural Oncology has a 12-month low of $2.87 and a 12-month high of $5.46. The stock has a 50 day simple moving average of $3.83 and a 200 day simple moving average of $3.58. The stock has a market cap of $64.68 million, a P/E ratio of -0.42 and a beta of 3.66.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a report on Monday, November 11th.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Articles
- Five stocks we like better than Mural Oncology
- What Are Trending Stocks? Trending Stocks Explained
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- How to Profit From Value Investing
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Learn Technical Analysis Skills to Master the Stock Market
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
